XML 76 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 10, 2021
USD ($)
shares
Nov. 30, 2021
USD ($)
shares
Sep. 30, 2020
USD ($)
shares
Aug. 31, 2020
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
Mar. 31, 2021
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Shares reserved for future issuance         136,314,305   136,314,305   278,819,076
Exchange ratio of common stock             2.293698169    
Shares Available for Grant, Beginning balance         66,252,927   66,252,927   29,375,026
Stock Options, Granted             4,798,281    
Shares Available for Grant, Exercised             3,945,200    
Weighted-average grant date fair values of options granted | $ / shares             $ 9.64 $ 2.93  
Intrinsic value of vested options exercised | $             $ 19,200,000 $ 7,800,000  
Unrecognized stock-based compensation cost | $         $ 90,200,000   $ 90,200,000    
Weighted average period over which unrecognized compensation is expected to be recognized             2 years 4 months 24 days    
Stock-based compensation expense | $         17,409,000 $ 14,995,000 $ 37,473,000 35,496,000  
Proceeds from stock options exercised | $             11,476,000 38,210,000  
Lemonaid Health, Inc. [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Vesting period   4 years              
Unrecognized stock-based compensation cost | $   $ 42,100,000              
Weighted average period over which unrecognized compensation is expected to be recognized   3 years 9 months 18 days              
General and Administrative Expense [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock-based compensation expense | $         7,436,000 6,836,000 12,937,000 16,423,000  
General and Administrative Expense [Member] | Lemonaid Health, Inc. [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock-based compensation expense | $         1,800,000   1,800,000    
Stock Option Activity [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Tax benefit arising from stock option exercises | $         0 $ 0 0 $ 0  
Restricted Stock Units [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Unrecognized stock-based compensation cost | $         $ 97,600,000   $ 97,600,000    
Weighted average period over which unrecognized compensation is expected to be recognized             3 years 7 months 6 days    
Early Exercise of Common Stock Options [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock Options, Granted       3,000,000          
Shares Available for Grant, Exercised     3,000,000            
Proceeds from stock options exercised | $     $ 34,700,000            
Maximum [Member] | Restricted Stock Units [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Vesting period             4 years    
Minimum [Member] | Restricted Stock Units [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Vesting period             1 year    
2021 Incentive Equity Plan [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Exercise price of stock options as a percentage of fair value of shares             110.00%    
Share-based payment award, description             The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting in 2022, in an amount equal to (i) 22,839,019 shares of Class A common stock, (ii) 3.0% of the aggregate number of shares of Class A common stock and Class B common stock outstanding, or (iii) a lesser number of shares determined by the Company’s Board of Directors prior to the applicable January 1.    
Share-based payment award, expiration period             10 years    
Share-based compensation terms of award             Options under the 2021 Plan have a contractual life of up to ten years. The exercise price of a stock option shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors.    
2021 Incentive Equity Plan [Member] | Stock Option Activity [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Percentage of total stock holding         10.00%   10.00%    
2021 Incentive Equity Plan [Member] | Minimum [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Exercise price of stock options as a percentage of fair value of shares             100.00%    
ESPP [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Payroll deductions to participate in plan 15.00%                
2006 Equity Incentive Plan                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock Options, Granted             0    
2006 Equity Incentive Plan | Performance Based Awards [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Stock Options, Granted             0    
Class A Common Stock [Member] | Lemonaid Health, Inc. [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Common stock granted subject to vest   3,747,027              
Common stock granted subject to vest, Weighted average grant date fair value | $   $ 43,900,000              
Class A Common Stock [Member] | 2021 Incentive Equity Plan [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Shares reserved for future issuance 136,000,000                
Exchange ratio of common stock             2.293698169    
Shares Available for Grant, Beginning balance         22,839,019   22,839,019    
Common stock issued and outstanding, percentage             3.00%    
Class A Common Stock [Member] | 2021 Incentive Equity Plan [Member] | Lemonaid Health, Inc. [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Shares reserved for future issuance   2,990,386              
Class A Common Stock [Member] | 2021 Incentive Equity Plan [Member] | Maximum [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Shares reserved for future issuance 136,000,000                
Class A Common Stock [Member] | ESPP [Member]                  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]                  
Shares reserved for future issuance 11,420,000                
Common stock issued and outstanding, percentage 1.00%                
Potential annual increase in shares reserved for future issuance 5,000,000                
Discount from market price, offering date 85.00%                
Discount from market price, purchase date 85.00%                
Maximum value of shares per employee | $ $ 25,000                
Number of shares issued             0